A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3819469
Latest Information Update: 26 Dec 2023
At a glance
- Drugs Lepodisiran (Primary)
- Indications Cardiovascular disorders; Metabolic disorders
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 13 Nov 2023 Results (n=48) assessing safety, tolerability, pharmacokinetics (PK), and effects on Lp(a) serum concentrations after administration of single doses of lepodisiran, presented at the American Heart Association Scientific Sessions 2023.
- 18 Nov 2022 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 18 Nov 2022 to 8 Nov 2022.